John Maraganore on the ORION-11 Phase 3 Results
2:39
Who We Are: Alnylam's Core Values
2:19
Get to Know Alnylam - The Leader in RNAi Therapeutics
3:27
RNAi Therapeutics - How this New Class of Medicines Works
2:23
Alnylam（アルナイラム）企業紹介 - RNAi治療のリーディングカンパニー
3:32
RNAi, vielversprechendes Potenzial für eine neue Klasse von Medikamenten
3:34
Pathophysiology of Acute Hepatic Porphyria (AHP)
3:39
Kim – Living with Primary Hyperoxaluria Type 1
2:19